NH TherAguix appoints Vincent Carrère as Chief Executive Officer

PRESS RELEASE

Paris, France, Sept 12, 2023

NH TherAguix SA ("NHT"), a late-stage biotech company developing AGuIX®, a nanodrug to treat radiotherapy eligible tumours and metastases across oncology indications, today announced the appointment of Vincent Carrère as Chief Executive Officer (CEO).

Vincent Carrère brings more than 15 years’ experience in various Corporate and Commercial Operations leadership positions in the biotechnology and pharmaceutical industry and joins NHT from Ipsen where he last was Vice President - Head of the Northern and Central Europe Region. Vincent Carrère succeeds co-founder Géraldine Le Duc who has served as CEO since the Company’s inception in 2015. Géraldine will remain on the Executive Leadership Team as CSO/COO and member of the Board of Directors of NHT.

“We are delighted to welcome Vincent to lead NH TherAguix through the next phases of its development. The company’s lead drug candidate - AGuIX® - is currently evaluated in 4 Phase II randomized trials to address the high unmet medical needs of patients with tumours and metastases who undergo radiotherapy treatment. Vincent’s leadership and experience in strategy, business development and commercial operations in the oncology space, provide a unique skillset to the team as we progress our lead program to the late-stage clinic and commercialization. On behalf of the Board, I would like to thank Géraldine...
Vincent Carrère, CEO, added, “I am honoured and humbled to be joining NH Theraguix at this exciting time. The Company’s lead program to treat brain metastases aims at demonstrating a meaningful clinical impact for patients by enhancing tumour sensitization to radiotherapy without altering healthy tissues. The promising Phase 1 clinical data generated with AGuIX® confirmed the safety and clinical efficacy potential of this asset and I am convinced that the ongoing clinical trials could deliver additional data to support the acceleration of our ambitious clinical development program. I look forward to working with the talented team at NH TherAguix and progressing the Company’s nanodrug platform that has the potential to transform patients’ lives in indications with high unmet medical needs such as glioblastoma, pancreas or lung cancers.”

“It has been a privilege and a real happiness to bring AGuIX® from benchtop to readiness for late stage. I am extremely thankful to all the people - early-stage shareholders, VC investors, external and internal collaborators - who have supported the creation and development of NHT over the last 8 years.” stated Géraldine Le Duc, NH TherAguix CSO/COO. “Vincent has an outstanding track record as a global biopharma leader and his deep expertise in product development and commercialisation in solid tumours will be invaluable in NHT’s next stage of growth. I will be closely working with him to ensure the project’s future success.”

During his time at Ipsen, Vincent Carrère was leading commercial operations in +20 countries across the Northern & Central Europe Region and the company’s therapeutic areas of focus, including Oncology, driving double digit brand growth. Prior to that he served as a General Manager in Greece at Ipsen, where he was instrumental in shaping the organisation and launching products in multiple indications in the oncology field. Before joining commercial operations, he led the Corporate Strategic Planning Team, supported various Business Development efforts and was a Chief of Staff to Ipsen CEOs Marc de Garidel and David Meek. Prior to Ipsen, he was a Strategy and Management consultant at Capgemini Consulting, specialized in the Life Sciences sector. Vincent brings a wealth of experience working across different markets including US, Europe and China.

Vincent Carrère holds a Master's Degree in Management from ESCP-Europe.

Further information: Florence Cruz
Communications contact details
Email: cruz@nhtheraguix.com
Phone: +33 6 63 43 16 96

Notes for Editors
About NH TherAguix (www.nhtheraguix.com):

NH TherAguix is a late-stage biotech company developing AGuIX® to treat tumours and metastases in patients treated by radiotherapy. It is estimated that c.60% of cancer patients undergo radiotherapy treatment today.
AGuIX® is currently assessed in 4 Phase II randomized trials in brain metastases using either whole brain radiation therapy (NANORAD2, CHUGA, Grenoble, France) or stereoradiosurgery (NANOBRAINMETS, Dana Farber Brigham Cancer Center, Boston, USA), in glioblastoma (NANOGBM, multicentric, Clermont Ferrand, France) as well as in pancreatic and lung cancers (NANOSMART, Dana Farber Brigham Cancer Center, Boston, USA).
Results of the First in Human Phase I trial in brain metastases (NANORAD1, CHUGA, Grenoble, France) have confirmed AGuIX® safety and efficacy profile (Verry et al, Science Advances 2020, Verry et al. Radiotherapy & Oncology, 2021).
AGuIX® has been extensively tested in various preclinical models and the results published more than 80 times in high impact publications. This innovation is protected by 18 patent families.
NH TherAguix was established in 2015 after 10 years of academic research in the founders’ laboratories that led to the invention of AGuIX® and the discovery of its radiosensitizing effect.
Altogether, NH TherAguix raised around €40M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova.